偉思醫療(688580.SH):已具備腦電採集、無創神經調控、康復機器人等技術
格隆匯3月20日丨偉思醫療(688580.SH)在投資者互動平台表示,公司目前在神經康復領域的技術佈局已從單一設備向“診斷-治療-康復”全週期解決方案延伸,針對閉環神經康復系統,公司已具備腦電採集、無創神經調控、康復機器人等技術,根據實際臨牀需求,可以實現“腦信號採集-意圖解析-磁刺激調控-機械輔助執行”的閉環康復鏈:①對於中風後遺症患者,可通過腦電帽實時捕捉運動想象信號,同步觸發康復機器人執行訓練,同時利用經顱磁刺激(TMS)增強神經可塑性,加速運動功能重建;②對於脊髓損傷患者,公司表面肌電分析系統可評估殘存神經功能,結合脈衝磁場治療儀干預受損眷髓節段,形成個性化康復方案。依託本次政策支持,公司將密切關注神經科學前端技術發展與運用情況,助力推進康復醫學向精準化、智能化跨越發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.